Pierre S. Sayad's most recent trade in Fennec Pharmaceuticals Inc was a trade of 12,000 Common Shares done at an average price of $12.2 . Disclosure was reported to the exchange on Aug. 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 31 Aug 2026 | 12,000 | 9,519 (0%) | 0% | 12.2 | 146,160 | Common Shares |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2026 | 168 | 21,519 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2026 | 168 | 21,351 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2026 | 168 | 21,183 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2026 | 168 | 21,015 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 168 | 20,847 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2026 | 120,000 | 270,000 | - | - | Stock Options | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 18,456 | 18,456 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 2,052 | 20,679 (0%) | 0% | 0 | Common shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 171 | 18,627 (0%) | 0% | 0 | Common shares | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 10,000 | 160,000 | - | - | Restricted Share Unit | |
| Fennec Pharma Inc | Pierre S. Sayad | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2024 | 150,000 | 150,000 | - | - | Stock Options |